Stéphane Bancel is a French business executive best known for his long-standing leadership as the chief executive officer of Moderna, the American biotechnology company that gained global prominence for its development of messenger RNA (mRNA) technology and the COVID-19 vaccine. Born on July 20, 1972, in Marseille, France, Bancel’s career has been characterized by a transition from traditional pharmaceutical manufacturing and diagnostics to the cutting edge of genomic medicine. Bancel’s academic background is rooted in engineering and business. He earned a Master of Engineering degree from CentraleSupélec (formerly École Centrale Paris) and a Master of Science in chemical engineering from the University of Minnesota. He later completed a Master of Business Administration (MBA) from Harvard Business School, providing him with a dual foundation in technical sciences and corporate strategy that would define his professional trajectory. His early career began in the late 1990s and early 2000s, where he gained significant experience in the global pharmaceutical industry. From 2000 to 2006, Bancel held several leadership positions at Eli Lilly and Company, including serving as the managing director for Belgium and as an executive director of global manufacturing strategy and supply chain. Prior to his tenure at Eli Lilly, he worked as the Asia-Pacific sales and marketing director for the French diagnostics company bioMérieux. He returned to bioMérieux in 2007 to serve as its chief executive officer, a role he held until 2011. During his time at bioMérieux, he was credited with improving the company's financial margins and global operations. In 2011, Bancel joined the board of directors of the nascent biotechnology company Moderna, which had been founded just a year prior. In October of that same year, he was appointed CEO of the company. Under his leadership, Moderna pivoted toward the ambitious goal of harnessing mRNA technology to create a new class of prophylactic and therapeutic medicines. Bancel steered the company through its formative years as a private venture, ultimately leading Moderna to a successful initial public offering (IPO) in December 2018, which was the largest in the history of the biotechnology industry at that time. The most defining period of Bancel’s career occurred in 2020, following the emergence of the SARS-CoV-2 virus. Under his direction, Moderna mobilized its mRNA platform to develop a vaccine candidate (mRNA-1273) in record time. The company received Emergency Use Authorization from the U.S. Food and Drug Administration in December 2020, followed by full FDA approval for the vaccine—marketed as Spikevax—in January 2022. This achievement solidified Bancel’s reputation as a key figure in global public health responses to the pandemic. Beyond his role at Moderna, Bancel has been a special partner at Flagship Pioneering, the venture capital firm that incubated Moderna, since 2013. He has also served on the boards of several other organizations, including Indigo Agriculture and Qiagen. His professional contributions have earned him various recognitions, including his nomination as a Chevalier of the Legion d'honneur in France in 2022 and his election to the U.S. National Academy of Engineering in 2024. Bancel resides in the Boston area with his wife and two children.